Alembic enters into licensing pact with Belgian co
24 May 2007
Mumbai: Drug maker Alembic has signed a licensing
agreement with Belgian drugmaker UCB, a global biopharmaceutical
company, engaged in R&D and commercialisation of pharmaceutical
and biotechnology products in the fields of central nervous
system disorders, for its Novel Drug Delivery Platform
for epilepsy drug Keppra XR (Levetiracetam extended release
tablets).
As per the agreement, Alembic will provide the technology to reduce the dosage for the twice-a-day Keppra drug to make it a once-a-day tablet. The tablet will then be sold in dosages of 500 mg, 1000 mg and 1500 mg and will be called Keppra XR.
Alembic would receive milestone payments of $11 million and additionally get royalty payments on future worldwide net sales of the Keppra drug, subject to necessary legal and regulatory approvals. Phase III clinical trials on Keppra XR (Levetiracetam Extended Release tablets) are ongoing and results are expected in the fourth quarter of 2007, the company said.
Keppra is UCB''s leading anti-epileptic drug, with sales of 761 million ($1 billion) in 2006.
In
2006 UCB had a turnover of $2.5 billion.
Latest articles
Featured articles
The remarkable Ratan Tata
By Kiron Kasbekar | 23 Oct 2024
One newspaper report of Ratan Tata’s passing away showed an old photo of him climbing into the cockpit of a Lockheed Martin F-16 fighter.
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation